Interest in nonpharmaceutical supplements for treating major depressive disorder (MDD) has increased significantly, both among patients and among clinicians during the past decades. Despite the large array of antidepressants (ADs) available, many patients continue to experience relatively modest response and remission rates, in addition to a burden of side effects that can hinder treatment compliance and acceptability. In this article, we review the literature on folates and S-adenosylmethionine (SAMe), 2 natural compounds linked in the 1-carbon cycle metabolic pathway, for which substantial evidence supports their involvement in mood disorders. Background information, efficacy data, proposed mechanisms of action, and side effects are reviewed. Based on existing data, supplementation with SAMe, as well as with various formulations of folates, appears to be efficacious and well tolerated in reducing depressive symptoms. Compared with other forms of folates, 5-methyltetrahydrofolate (L-methylfolate or 5-MTHF) may represent a preferable treatment option for MDD given its greater bioavailability in patients with a genetic polymorphism, and the lower risk of specific side effects associated with folic acid. Although further randomized controlled trials in this area appear warranted, SAMe and L-methylfolate may represent a useful addition to the AD armamentarium.
BottiglieriT.S-adenosyl-L-methionine (SAMe): From the bench to the bedside-molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002;76(5):1151S–1157S.
2.
BaldessariniRJ. The neuropharmacology of S-adenosyl-L-methionine. Am J Med. 1987;83:95–103.
3.
PapakostasGIAlpertJEFavaM.S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003;5(6):460–466.
4.
MischoulonDFavaM.Role of S-adenosyl-L-methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr. 2002;76(5):1158S–1161S.
5.
BottiglieriTLaundryMCrellinR, Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69:228–232.
6.
BottiglieriTHylandKLaundryM, Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med. 1992;22:871–876.
7.
Abou-SalehMTCoppenA.Serum and red blood cell folate in depression. Acta Psychiatr Scand. 1989;80(1):78–82.
8.
CarneyMWSheffieldBF. Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med. 1978;8(1):139–144.
9.
WessonVALevittAJJoffeRT. Change in folate status with antidepressant treatment. Psychiatry Res. 1994;53:313–322.
10.
LeeSWingYKFongS.A controlled study of folate levels in Chinese inpatients with major depression in Hong Kong. J Affect Disord. 1998;49:73–77.
11.
GhadirianAMAnathJEngelsmanF.Folic acid deficiency in depression. Psychosomatics. 1980;21:926–929.
12.
TiemeierHvan TuijlHRHofmanA, Vitamin B12, folate, and homocysteine in depression: The Rotterdam Study. Am J Psychiatry. 2002;159(12):2099–2101.
13.
MorrisMSFavaMJacquesPF, Depression and folate status in the US population. Psychother Psychosom. 2003;72:80–87.
14.
WilkinsonAMAndersonDNAbou-SalehMT, 5-Methyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECT. J Affect Disord. 1994;32:163–168.
15.
FavaMBorusJSAlpertJE, Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997;154(3):426–428.
16.
PapakostasGIPetersenTMischoulonD, Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: Predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004;65(8):1090–1095.
17.
PapakostasGIIosifescuD VRenshawPF, Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005;140(3):301–307.
18.
PapakostasGIPetersenTLebowitzBD, The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005;8(4):523–528.
19.
AlpertMSilvaRRPougetER. Prediction of treatment response in geriatric depression from baseline folate level: Interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309–313.
20.
LevittAJWessonVAJoffeRT. Impact of suppression of thyroxine on folate status during acute antidepressant therapy. Psychiatry Res. 1998;79:123–129.
21.
ReynoldsEHPreeceJMBaileyJ, Folate deficiency in depressive illness. Br J Psychiatry. 1970;117:287–292.
22.
HectorMBurtonJR. What are the psychiatric manifestations of vitamin B12 deficiency?J Am Geriatr Soc. 1988;36(12):1105–1112.
23.
BellIREdmanJSMorrowFD, B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc. 1991;39(3):252–257.
24.
AlarconRDTolbertLCMontiJA, One-carbon metabolism disturbances in affective disorders. A preliminary report. J Affect Disord. 1985;9(3):297–301.
25.
SmythiesJRAlarconRDMorereD, Abnormalities of one-carbon metabolism in psychiatric disorders: Study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes. Biol Psychiatry. 1986;21(14):1391–1398.
26.
BjellandITellGSVollsetSE, Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: The Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003;60(6):618–626.
27.
ArinamiTYamadaNYamakawa-KobayashiK, Methylenetetrahydrofolate reductase variant and schizophrenia/ depression. Am J Med Genet. 1997;74(5):526–528.
KellyCBMcDonnellAPJohnstonTG, The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004;18(4):567–571.
30.
KimJMStewartRKimSW, Modification by two genes of associations between general somatic health and incident depressive syndrome in older people. Psychosom Med. 2009;71(3):286–291.
31.
LewisSJLawlorDADavey SmithG, The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006;11(4):352–360.
32.
SlopienRJasniewiczKMeczekalskiB, Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland. Maturitas. 2008;61(3):252–255.
33.
GilbodySLewisSLightfootT.Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol. 2007;165(1):1–13.
34.
AlmeidaOPMcCaulKHankeyGJ, Homocysteine and depression in later life. Arch Gen Psychiatry. 2008;65(11):1286–1294.
35.
López-LeónSJanssensACGonzález-Zuloeta LaddAM, Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13(8):772–785.
36.
LanctôtKLRapoportMJChanF, Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 2010;24(7–8):959–969.
37.
NaismithSHickieIWardPB, Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry. 2002;159(12):2096–2098.
38.
CrellinRBottiglieriTReynoldsEH. Folates and psychiatric disorders: Clinical potential. Drugs. 1993;45(5):623–636.
39.
PasseriMCucinottaDAbateG, Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging (Milano). 1993;5(1):63–71.
40.
GuaraldiGPFavaMMazziF, An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5(2):101–105.
41.
Di PalmaCUraniRAgricolaR, Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis of treatment. Curr Ther Res. 1994;55(5):559–567.
42.
GodfreyPSATooneBKCarneyMWP, Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392–395.
43.
CoppenABaileyJ.Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121–130.
44.
ReslerGLavieRCamposJ, Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15(3):145–152.
AlpertJEMischoulonDRubensteinGE, Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002;14(1):33–38.
47.
PapakostasGISheltonRZajeckaJ, L-methylfolate augmentation of selective serotonin reuptake inhibitors for major depressive disorder: Results of two randomized, double-blind trials. Poster presented at the 15th World Congress of Psychiatry, Buenos Aires, Argentina, 2011.
48.
NelsonJCPapakostasGI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–991.
49.
BauerMDopfmerS.Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427–434.
50.
FrankenburgFR. Folate supplementation: Is it safe and effective? [letter]. J Clin Psychiatry. 2009;70(5):767; author reply 767–769.
51.
MelikianVPatonA.Site of reduction and methylation of folic acid in man. Lancet. 1971;298:955–957.
52.
MasonJBDicksteinAJacquesPF, A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: A hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16:1325–1329.
53.
ColeBFBaronJASandlerRS, Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. JAMA. 2007;297(21):2351–2359.
54.
KimDHSmith-WarnerSASpiegelmanD, Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010;21:1919–1930.
55.
StevensVLMcCulloughMLSunJ, High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology. 2011;141(1):98–105.
56.
StahlSM. L-methylfolate: A vitamin for your monoamines. J Clin Psychiatry. 2008;69(9):1352–1353.
57.
MischoulonDFavaM.Are nutritional supplements ready for prime time?J Clin Psychiatry. 2008;69(9):1497–1498.
58.
PinzelloAAndreoliV.Le transmetilazioni SAM-dipendenti nelle sindromi depressive. Valutazione dell-effetto terapeutico della S-adenosilmetionina con la scala di Hamilton. Quad Ter Sper Suppl Bioch Biol Sper. 1972;X/2:3–11. Italian.
59.
FazioCAndreoliVAgnoliA, Effetti terapeutici e meccanismo d'azione della S-adenosil-L-metionina (SAMe) nelle sindromi depressive [Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes]. Minerva Med. 1973;64:1515–1529. [Article in Italian].
60.
AgnoliAFazioCAndreoliV, Disturbi neuropsichiatrici e transmetilazioni. Effetti terapeutici della S adenosil-L-metionina [Neuropsychiatric disorders and transmethylation: Therapeutic effects of S-adenosyl-L-methionine]. Clin Ter. 1975;75:567–579. [Article in Italian].
61.
ManteroMPatorinoPCaroleiA, Controlled double-blind study (SAMe-imipramine) in depressive syndromes. Minerva Med. 1975;66(78):4098–4101.
62.
AndreoliVCampedelliAMaffeiF.La S-adenosil-L-metionina (SAMe) in geropsichiatria: Uno studio clinico controllato “in aperto” nelle sindromi depressive. Minerva Psichiatr. 1978;25:172–180. Italian.
63.
BarberiAPusateriC.Sugli effetti clinici della S-adenosil-L-metionina (SAMe) nelle sindromi depressive dell'eta’ senile. Minerva Psichiatr. 1978;19:235–243. Italian.
64.
SalvadoriniFGaleoneFSabaP, Evaluation of s-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res. 1980;27:908–918.
65.
CarneyMWMartinRBottiglieriT, Switch mechanism in affective illness and S-adenosylmethionine. Lancet. 1983;1(8328):820–821.
66.
HardyMCoulterIMortonSC, S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ): 2002 [cited 2011 Oct 29]. Available from: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1a.section. 2161. Evidence Report/Technology Assessment no 64. AHRQ publication no 02-E034. Prepared by Southern California Evidence-based Practice Center under contract no 290-97-0001.
67.
MiccoliLPorroVBertolinoA.Comparison between the antidepressant activity of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli). 1978;33(3):243–255.
68.
ScarzellaRAppiottaA.Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Riv Sper Freniatr Med Leg Alien Ment. 1978;102:359–365. Italian.
69.
MonacoPQuattrocchiF.Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methionine or SAM) [Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methione or SAM)]. Riv Neurol. 1979;49(6):417–439. [Article in Italian].
70.
KüfferleBGrünbergerJ.Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. Adv Biochem Psychopharmacol. 1982;32:175–180.
71.
JanicakPGLinpinskiJDavisJM, S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci. 1988;25(3):306–313.
72.
Delle ChiaieRPancheriPScapicchioP.Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: Comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S–1176S.
73.
PancheriPScapicchioPChiaieRD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002;5(4):287–294.
74.
AgnoliAAndreoliVCasacchiM.Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res. 1976;13(1):43–54.
75.
MuscettolaGGalzenatiMBalbiA.SAMe versus placebo: A double blind comparison in major depressive disorders. Adv Biochem Psychopharmacol. 1982;32:151–156.
76.
De LeoD.S-adenosylmethionine as an antidepressant. Curr Ther Res. 1987;41(6):865–870.
77.
CarneyMWEdehJBottiglieriT, Affective illness and S-adenosyl methionine: A preliminary report. Clin Neurophrmacol. 1986;9(4):379–385.
78.
CarusoIPietrograndeV.Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med. 1987;83(5A):66–71.
79.
BottiglieriTGodfreyPFlynnT, Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096–1098.
80.
CastagnaALe GrazieCAccordiniA.Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: Effect of parenteral treatment with SAMe. Neurology. 1995;45(9):1678–1683.
81.
De VannaMRigamontiR.Oral S-adenosyl-L-methionine in depression. Curr Ther Res. 1992;52(3):478–485.
82.
BellKMPotkinSGCarreonD, S-adenosylmethionine blood levels in major depression: Changes with drug treatment. Acta Neurol Scand. 1994;89(154):15–18.
83.
SalmaggiPBressaGMNicchiaG, Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59(1):34–40.
84.
KaganBLSultzerDLRosenlichtN, Oral S-adenosylmethionine in depression: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990;147(5):591–595.
85.
FavaMRosenbaumJFBirnbaumR, The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand. 1992;86(1):42–45.
86.
AlpertJEPapakostasGMischoulonD, S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24(6):661–664.
87.
BerlangaCOrtega-SotoHAOntiverosM, Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44(3):257–262.
88.
PapakostasGIMischoulonDShyuI, S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942–948.
89.
CarneyMWCharyTKBottiglieriT, The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry. 1989;154:48–51.
90.
IruelaLMMinguezLMerinoJ, Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150(3):522.
